Pax2 is essential for proliferation and osteogenic differentiation of mouse mesenchymal stem cells via Runx2

Lu, Mengting; Guo, Shuyu; Hong, Fangling; Zhang, Yuxin; Yuan, Lichan; Ma, Castello; Ma, Junqing

doi:10.1016/j.yexcr.2018.08.026

Cited by 5 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RUNX2, located on chromosome 6p21, is one of the most critical transcription factors involved in osteoporosis, and its deficiency inhibits osteoblast differentiation, contributing to the development of diseases (33,34), including numerous bone-related diseases (35)(36)(37). The results of the present study determined that expression of RP11-84C13.1 was positively associated to RUNX2 and promoted osteogenic differentiation of hBMSCs.…”

Section: Discussionmentioning

confidence: 47%

“…siRNAs have been used to study a variety of diseases, including osteoporosis. By Alizarin Red staining, it was revealed that osteogenic differentiation of hBMSCs was induced by transfection of si-STAT5a for 14 days ( 38 ); osteogenic differentiation of mBMSCs was inhibited by transfection of si-KLF5 for 14 days ( 39 ); the osteogenic ability of CON-ASCs was decreased by transfection of si-Jkamp for 14 days ( 40 ); osteogenic differentiation of hJBMMSCs was reduced by transfection of si-SEMA3A for 14 days ( 37 ). In general, siRNAs have a short role time in cells, which may be attributed to the gradual dilution of siRNAs after transfection in cell replication, so that the gene silencing effect gradually disappears.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long non‑coding RNA RP11‑84C13.1 promotes osteogenic differentiation of bone mesenchymal stem cells and alleviates osteoporosis progression via the miR‑23b‑3p/RUNX2 axis

Tang

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

The objective of the present study was to determine the role of RP11-84C13.1 in osteoporosis (OP) and its molecular mechanism. First, clinical samples were collected from OP patients and normal control patients. Human bone marrow stromal cells (hBMSCs) were extracted from femoral head tissues. Runt-related transcription factor 2 (RUNX2) and RP11-84C13.1 serum levels were assessed by reverse transcription-quantitative (RT-q)PCR. Following transfection of pcDNA-RP11-84C13.1, si-RP11-84C13.1, microRNA (miRNA)-23b-3p mimic and miRNA-23b-3p inhibitor, the expression levels of RUNX2 and RP11-84C13.1 were determined by RT-qPCR. In addition, the osteogenic ability of hBMSCs was assessed by Alizarin Red staining. The binding of RP11-84C13.1 to miRNA-23b-3p and the binding of miRNA-23b-3p to RUNX2 was confirmed by dual-luciferase reporter gene assay. Long non-coding RNA (lncRNA) RP11-84C13.1 was significantly downregulated in the serum of OP patients. The osteogenic differentiation-related genes RUNX2 and RP11-84C13.1 were markedly upregulated in a time-dependent manner, while the miRNA-23b-3p level gradually decreased in hBMSCs with the prolongation of osteogenesis. RP11-84C13.1 knockdown inhibited the osteogenic differentiation of hBMSCs. Furthermore, RP11-84C13.1 regulated RUNX2 expression by targeting miRNA-23b-3p. Overexpression of miRNA-23b-3p partially reversed the promoting effect of RP11-84C13.1 on the osteogenesis of hBMSCs. In conclusion, lncRNA RP11-84C13.1 upregulated RUNX2 by absorbing miRNA-23b-3p, and thus induced hBMSC osteogenesis to alleviate osteoporosis.

show abstract

Section: Discussionmentioning

confidence: 47%

Section: Discussionmentioning

confidence: 99%

Long non‑coding RNA RP11‑84C13.1 promotes osteogenic differentiation of bone mesenchymal stem cells and alleviates osteoporosis progression via the miR‑23b‑3p/RUNX2 axis

Tang

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“… 32–34 ERK can regulate osteoblast proliferation by modulating cell cycle regulators. 35 Moreover, the results of previous studies have also confirmed that the osteogenic activity of Runx2 and OCN might be modified by phosphorylated MAPK, which could further promote their ability to bind with each other. 36 However, no reports on how HDAC9 regulates the osteogenic differentiation of MSCs through the MAPK signaling pathway have been published.…”

Section: Discussionmentioning

confidence: 77%

Knockdown of HDAC9 Inhibits Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells Partially by Suppressing the MAPK Signaling Pathway

Wang¹,

Gong²,

Han³

et al. 2022

CIA

View full text Add to dashboard Cite

Background Histone deacetylase 9 (HDAC9) is a member of the HDAC gene family that plays essential roles in the organization of transcriptional regulation by catalyzing deacetylation of histone proteins. However, the effects of HDAC9 on osteonecrosis of femoral head (ONFH) have not been investigated. The present study aimed to reveal whether histone deacetylase 9 (HDAC9) regulated osteogenic differentiation. Methods A lentiviral knockdown HDAC9 model was established in hBMSCs. Osteoblast-specific gene expression, such as Runx2, OCN was examined by qRT-PCR and Western blot, respectively. Though transcriptome sequencing and enrichment analysis, related signal pathways caused by down-regulation of HDAC9 were screened. The effect of HDAC9 on MAPK signaling pathway was determined by Western blot. Eventually, tert-Butylhydroquinone (tBHQ) was used to examine the effect of MAPK activation on osteogenesis in HDAC9 knockdown hBMSCs. Results A lentiviral knockdown HDAC9 model was successfully established in hBMSCs. HDAC9 knockdown significantly inhibited osteoblast-specific gene expression, such as runt-related transcription factor 2 (Runx2), osteocalcin (OCN) and mineral deposition in vitro. Moreover, a total of 950 DEGs were identified in HDAC9-knockdown hBMSCs. We discovered that the MAPK signaling pathway might be related to this process by pathway enrichment analysis. HDAC9 knockdown significantly reduced the expression level of phosphorylated extracellular signal-regulated kinase 1/2 (pERK1/2). Finally, the decreased osteogenesis due to HDAC9 knockdown was partly rescued by a MAPK signaling pathway activator. Conclusion Taken together, these results suggest that HDAC9 knockdown inhibits osteogenic differentiation of hBMSCs, partially through the MAPK signaling pathway. HDAC9 may serve as a potential target for the treatment of ONFH.

show abstract

Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways

Chen

Yan

Wang

et al. 2020

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Pax2 is essential for proliferation and osteogenic differentiation of mouse mesenchymal stem cells via Runx2

Cited by 5 publications

References 40 publications

Long non‑coding RNA RP11‑84C13.1 promotes osteogenic differentiation of bone mesenchymal stem cells and alleviates osteoporosis progression via the miR‑23b‑3p/RUNX2 axis

Long non‑coding RNA RP11‑84C13.1 promotes osteogenic differentiation of bone mesenchymal stem cells and alleviates osteoporosis progression via the miR‑23b‑3p/RUNX2 axis

Knockdown of HDAC9 Inhibits Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells Partially by Suppressing the MAPK Signaling Pathway

Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways

Contact Info

Product

Resources

About